首页> 外文期刊>Journal of research in medical sciences : >The assessment of hepatitis B seroprevalence in persons with intravenous drug use history in the Isfahan province: Community-based study
【24h】

The assessment of hepatitis B seroprevalence in persons with intravenous drug use history in the Isfahan province: Community-based study

机译:伊斯法赫省静脉注射史上乙型肝炎肝炎乙型肝炎的评估:以社区为基础的研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Hepatitis B with its complications has become one of the universal problems. Injection drug use is one of the most important risk factors in the transmission of hepatitis B. Therefore, we assessed hepatitis B virus prevalence among cases with a history of intravenous drug use (IVDU) as the first announcement-based study in this regard. Materials and Methods: The announcement-based detection of hepatitis B seroprevalence in volunteers with a history of intravenous drug use was conducted in the Isfahan province. A comprehensive community announcement was made in all the public places and to all physicians, in all the regions. One thousand five hundred and eighty-eight volunteers were invited to the Isfahan reference laboratories and serum samples were tested for HBs-Ag, HBc Ab, and HBs-Ab, using the enzyme-linked immunosorbent assay (ELISA) method. Results: In this study, 1588 individuals volunteered, who were estimated to be 50% of all the expected intravenous drug users in the community. HBs Ag was detected in 4.2% of them. HBc Ab and HBs Ab were detected in order in 11.4 and 17.3%, respectively. Conclusion: We estimated that the seroprevalence of hepatitis B positivity in intravenous drug users was moderate to high. Therefore, it was suggested that this group be encouraged to prevent acquiring infection by vaccination, education, counseling for risk reduction, and treatment of substance abuse, and finally hepatitis B virus (HBV) screening.
机译:背景:具有并发症的乙型肝炎已成为普遍问题之一。注射药物使用是乙型肝炎传播中最重要的风险因素之一。因此,我们评估了静脉注射药物使用历史(IVDU)的肝炎病毒患病率,作为这方面的第一个公布的研究。材料和方法:在伊斯法罕进行了静脉注射药物史上乙型肝炎乙型肝炎的乙型肝炎乙型肝炎的检测。在所有地区的所有公共场所和所有医生中都在全面的社区公告。使用酶联免疫吸附测定(ELISA)方法,邀请了一千五百八十八十八个志愿者,并测试了HBS-Ag,HBC AB和HBS-AB的血清样品。结果:在本研究中,1588人自愿服务,估计为社区中所有预期的静脉内吸毒者的50%。在其中的4.2%中检测到HBS AG。 HBC AB和HBS AB分别以11.4和17.3%的命令检测。结论:据估计,静脉注射药物乙型肝炎抗肝炎的Seroprevalence中普遍性中等至高。因此,有人建议鼓励该群体通过疫苗接种,教育,咨询风险降低和治疗药物滥用的治疗,以及最终乙型肝炎病毒(HBV)筛查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号